| 000 | 00924 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250514183016.0 | ||
| 264 | 0 | _c20040422 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a1540-0352 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, David | |
| 245 | 0 | 0 |
_aThird annual meeting of the Society of Urologic Oncology: Bethesda, Maryland, December 13-14, 2002. _h[electronic resource] |
| 260 |
_bClinical prostate cancer _cMar 2003 |
||
| 300 |
_a203-6 p. _bdigital |
||
| 500 | _aPublication Type: Congress | ||
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aFinasteride _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMedical Oncology |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 | _aSocieties, Medical |
| 650 | 0 | 4 | _aUrology |
| 773 | 0 |
_tClinical prostate cancer _gvol. 1 _gno. 4 _gp. 203-6 |
|
| 999 |
_c14758046 _d14758046 |
||